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subset and their nominal power, with higher fraction of as-
sociated SNPs and higher nominal power leading to more 
power improvement. The power improvement can be sub-
stantial; for disease loci not included in the prioritized sub-
set, the power loss is almost negligible.  Conclusion: The PSA 
has the flexibility of allowing investigators to combine prior 
information from a variety of sources, and will be a useful 
tool for GWAS.  Copyright © 2007 S. Karger AG, Basel
 Introduction
 Genome-wide association studies (GWAS) have now 
become feasible due to recent developments in genotyp-
ing technologies, a rapid decline in genotyping costs  [1–
3] , and the completion of the International HapMap Proj-
ect  [4] . In GWAS, investigators typically rely on commer-
cial genotyping products that attempt to provide adequate 
coverage across the genome. However, many times an 
 investigator may have prior knowledge, e.g., candidate 
genes or evidence for linkage, where dense coverage 
might be desirable. Unfortunately, commercial genotyp-
ing products for GWAS typically have variation in cover-
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 Abstract
 Background: Genome-wide association studies (GWAS) are 
now feasible for studying the genetics underlying complex 
diseases. For many diseases, a list of candidate genes or re-
gions exists and incorporation of such information into data 
analyses can potentially improve the power to detect dis-
ease variants. Traditional approaches for assessing the over-
all statistical significance of GWAS results ignore such infor-
mation by inherently treating all markers equally.  Methods: 
We propose the prioritized subset analysis (PSA), in which a 
prioritized subset of markers is pre-selected from candidate 
regions, and the false discovery rate (FDR) procedure is car-
ried out in the prioritized subset and its complementary sub-
set, respectively.  Results: The PSA is more powerful than the 
whole-genome single-step FDR adjustment for a range of 
alternative models. The degree of power improvement de-
pends on the fraction of associated SNPs in the prioritized 
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age across the genome and do not allow for flexible selec-
tion of SNPs, leaving investigators with little control over 
what regions should receive high coverage. In the face of 
such restrictions, the commonly used approach of carry-
ing out a single multiple-testing adjustment may not be 
efficient because regions with little relevance to a study 
might receive dense coverage and unnecessarily increase 
the number of hypothesis tests. The standard single-step 
adjustment ignores prior knowledge of potentially prom-
ising regions, and as a result, tests of significance for 
SNPs in such regions may be overly down-weighted due 
to the other relatively unpromising SNPs. In this situa-
tion, it could be more powerful to use prior information 
to prioritize genomic regions in data analysis.
 Recognizing this problem, Genovese et al.  [5] and 
 Roeder et al.  [6] introduced a method in which the asso-
ciation analysis p value for each SNP is up- or down-
weighted and then the resulting weighted p values are 
subsequently used in the false discovery rate (FDR) pro-
cedure  [7] . Roeder et al.  [6] illustrated this weighted FDR 
approach by defining weights according to linkage analy-
sis information, and showed that their method is more 
powerful than the standard FDR procedure using the 
original p values. However, in many studies, linkage in-
formation is not available for the disease and population 
of interest, and even when available, linkage evidence 
may be contradictory across different linkage studies. In 
addition, an investigator might wish to incorporate infor-
mation on biologically relevant candidate genes, which 
do not necessarily fall within linkage peak regions, in the 
analysis. While the proposed method of Roeder et al.  [6] 
can be applied outside the linkage setting to give in-
creased weight to candidate SNPs, it remains unclear how 
such weights should be assigned, especially when multi-
ple sources of prior information with different levels of 
evidence are available.
 Sun et al.  [8] proposed a stratified FDR method in 
which the genome is partitioned into subsets based on a 
set of criteria and the FDR procedure is applied to each 
subset. They evaluated the performance of this approach 
on 198,345 SNPs typed to test for association with Par-
kinson’s disease  [9] . They partitioned the association re-
sults into two subsets based on the minor allele frequen-
cies (MAFs) and applied the FDR procedure separately to 
the two subsets. While MAF is related to the power to 
detect disease association, it has little relevance with pri-
or biological information and thus partitioning based on 
MAF probably would not lead to noticeable power im-
provement. In fact, using the stratified FDR approach, 
Sun et al.  [8] demonstrated that stratification on MAF 
provided no distinct advantage over non-stratified analy-
sis. Although Sun et al.  [8] mentioned the potential of us-
ing alternative stratification approaches, such as candi-
date genes and linked regions, they did not evaluate the 
advantage of these alternatives.
 In this paper, we propose Prioritized Subset Analysis 
(PSA) in which the genome is partitioned into regions of 
high and low priority, with high priority regions defined 
on the basis of prior evidence for disease variants, and the 
FDR procedure is performed separately on the prioritized 
subset and in the complementary, non-prioritized subset. 
Unlike the weighted FDR approach  [5, 6] , PSA does not 
explicitly assign weights to the SNPs. We demonstrate 
that the PSA, an approach that is intuitive and easy to 
implement, is more powerful than the whole-genome sin-
gle-step FDR adjustment. We also investigate factors – 
sizes of prioritized regions, fraction of disease regions 
and their effect sizes in the prioritized subset – that influ-
ence the power of the PSA and their effect on the overall 
FDR.
 Methods
 Prioritized Subset Analysis
 A commonly used multiple-comparison adjustment in GWAS 
is the whole-genome single-step FDR adjustment (abbreviated as 
whole-genome adjustment or WGA). When prior information 
such as candidate genes or regions of linkage is available, results 
within highly promising genomic regions might be overly down-
weighted due to inclusion of tests in relatively unpromising ge-
nomic regions. To address this problem, we propose to partition 
the complete set of SNPs into two distinct subsets of SNPs. The 
‘prioritized’ subset of SNPs consists of SNPs in regions that have 
been identified to be more likely to harbor disease susceptibility 
variants. The ‘complimentary’ subset of SNPs consists of all re-
maining SNPs not assigned to the ‘prioritized’ subset. We then 
perform the FDR adjustment twice, once on the prioritized subset 
of SNPs and once on the complementary, non-prioritized subset, 
of SNPs. The two FDR procedures use the same error rate, which 
is the overall target error rate. We call this approach the Priori-
tized Subset Analysis (PSA). We note that this approach does not 
involve assigning weights to either the prioritized or complimen-
tary set of SNPs. By defining the prioritized subset, we wish to 
incorporate prior knowledge pertaining to the genetics of the 
phenotype of interest into GWAS, with the hope of improving the 
power while controlling the genome-wide error rate at desired 
level.
 FDR Procedure
 The FDR procedure, originally introduced by Benjamini and 
Hochberg  [7] , is commonly used to control the global error rate 
in multiple-testing problems. The FDR controls the expected 
fraction of false positives among significant findings. Let  R be the 
total number of rejections,  V  be the number of false rejections, 
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and  Q =  V / R when  R  1 0 and  Q = 0 otherwise. The FDR is the ex-
pectation E( Q ) of  Q . The number of true positives is  R –  V . In 
practice, the FDR procedure operates as follows. Let  m be the total 
number of genetic markers, and  H i  ( i = 1, ...,  m ) be the null hy-
pothesis of no association between marker  i and the outcome of 
interest. For each null hypothesis  H i , a statistical test is carried 
out. Let  P (1)   ̂   P (2)   ̂  ...  ̂   P ( m )  denote the ordered p values ob-
tained from these  m hypothesis tests. For a given FDR level  q , the 
ordered p value  P ( i )  is compared with the critical value  i    q / m . Let 
 k = max{ i :  P ( i )   ̂   i   q / m } be the largest index  i such that  P ( i )   ̂  
 i    q / m . If such a  k exists, then the hypotheses corresponding to 
the  k smallest p values are rejected.
 Benjamini and Hochberg  [7] proved that when the tests are 
mutually independent, the FDR of this procedure will be under 
control, that is, E( Q )  ̂   qm 0 / m  ̂   q , where  m 0  is the number of 
tests for which the null hypothesis is true. However, in GWAS, 
nearby SNPs are often in linkage disequilibrium (LD), leading to 
dependency among tests. Benjamini and Yekutieli  [10] proved 
that the FDR will be under control when the test statistics have 
positive regression dependency. Because markers in LD tend to 
result in positively correlated tests, one intuitively would expect 
this property to hold for genetic association analysis and hence 
the FDR to be under control. Using simulations, Sabatti et al.  [11] 
showed this to be true for case-control studies.
 Properties of the PSA
 Let  R 1  be the number of rejections and  V 1  be the number of 
false rejections in the prioritized subset. Similarly, let  R 2  and  V 2  
denote the corresponding numbers for the non-prioritized sub-
set. Then, the total number of rejections is  R =  R 1  +  R 2 , and the 
total number of false rejections is  V = V 1  +  V 2 . For each subset, the 
FDR will be under control. Intuitively, one might expect that the 
overall FDR is also under control, because for a data set, if  Q 1  = 
 V 1 / R 1   ̂   q and  Q 2  =  V 2 / R 2   ̂   q , then  Q =  V / R = ( V 1  +  V 2 )/( R 1  +  R 2 ) 
 ̂  ( R 1 q +  R 2 q )/( R 1  +  R 2 ) =  q . However, the FDR procedure only 
guarantees E[ Q 1 ]  ̂   q and E[ Q 2 ]  ̂   q , which does not necessarily 
lead to E[ Q ]  ̂   q . Therefore, we carried out simulations to inves-
tigate the effect of PSA on the overall FDR.
 One interesting aspect of the FDR procedure is that the chance 
of rejecting a test depends not only on the test itself, but also on 
other tests. The chance increases when the fraction of tests under 
the alternative hypotheses or their nominal power increases; in 
other words, a test can ‘borrow the strength’ from the other tests. 
In the PSA, when the prioritized subset is defined such that it in-
cludes most disease gene regions or disease loci with relatively 
strong effect, the prioritized subset will, compared to the whole 
set, have a higher fraction of tests under the alternative hypoth-
eses or relatively higher nominal power. As a result, for a SNP that 
is included in the prioritized subset, the PSA will likely have high-
er power to detect association with the disease than the WGA. On 
the other hand, if a disease gene region is not included in the pri-
oritized subset, the PSA might lead to a loss of power compared 
to the WGA. We carried out simulations to demonstrate this pow-
er loss is often negligible. A similar phenomenon was also ob-
served for the weighted FDR procedure proposed by Genovese et 
al.  [5] and Roeder et al.  [6] .
 Simulations
 We carried out simulations to evaluate the performance of the 
PSA, its effect on the overall FDR, and the change in power when 
a disease gene region is not included in the prioritized subset. To 
give a practical evaluation of the PSA, we analyzed simulated 
GWAS data sets with LD patterns resembling real data as derived 
from the HapMap.
 HapMap Data
 Phased genotype data for the 60 CEU (CEPH samples with 
ancestry from northern and western Europe) founder subjects 
were obtained from HapMap release #21 (www.hapmap.org). We 
also obtained SNP names and positions for Illumina Sentrix  
HumanHap300 BeadChips (317,503 SNPs). After merging with 
the HapMap phased data, 314,174 (99.0%) SNPs remained and 
were used for our simulations.
 Disease Model
 We considered a six-locus disease model assuming the disease 
loci are independent and reside on different chromosomes. We 
generated a model in which three of these disease loci have small 
effect (locus-specific sibling recurrence risk   s  = 1.02, genotypic 
relative risk or GRR  ; 1.34) and the others have relatively large 
effect (locus-specific   s  = 1.05, GRR  ; 1.57). We note that   s  = 
1.05 is similar to the effect size of  TCF7L2,  a  recently identified 
type 2 diabetes susceptibility gene  [12] . To assess the impact of lo-
cal LD on power, the three small effect disease loci were placed in 
regions with weak, moderate, and strong LD, respectively, and
the three large effect disease loci were placed similarly. Using 
these criteria, we picked three SNPs on chromosomes 6, 10, and 5
(MAF = 0.25, 0.36, 0.33), as the disease loci that confer small dis-
ease risk, and three SNPs on chromosomes 3, 11, and 4 as the dis-
ease loci with relatively large effect (MAF = 0.43, 0.31, 0.30). These 
minor allele frequencies are similar to putative disease variants 
identified in the first GWAS reported for type 2 diabetes  [13] . The 
disease chromosomes were randomly chosen according to de-
sired LD levels and the results would not change dramatically if 
other chromosomes with similar LD patterns were chosen as dis-
ease loci.
 The minor alleles were designated as the risk alleles. We 
 assigned penetrances as Pr(affected  genotype) = 1/[1 + exp
(–  0  –   6 i  = 1    i   g i )], where  g i   D {0,1,2} is the number of risk alleles 
at disease locus  i . This is equivalent to assuming multiplicative 
effect across disease loci on the odds scale. The parameters   i  were 
chosen so that the locus-specific   s  = 1.02 for  i = 1, 2, 3 and   s  = 
1.05 for  i = 4, 5, 6; the intercept   0  was chosen so that the popula-
tion disease prevalence was 5%.  Figure 1 shows the locations of 
disease loci and nearby SNPs on the Illumina HumanHap300 
SNP panel, and the LD as measured by  r 2  between the disease loci 
and the nearly SNPs.
 Simulation of Case-Control Data
 We generated 1,000 replicate data sets containing genotype 
data from 500 unrelated cases and 500 unrelated controls. For 
each individual, we first generated the genotypes at the pre-deter-
mined disease loci according to the disease model described 
above, and assigned one allele to each of the two chromosomes 
carried by that individual. The remaining genotypes of each chro-
mosome were generated using the algorithm of Durrant et al.  [14] . 
Let d denote the disease locus. For each chromosome, given the 
allele at  d , the algorithm starts by picking, at random, a five-SNP 
haplotype at loci [ d – 2,  d + 2] from the 120 CEU founder chro-
mosomes that has the same allele at  d . The algorithm then gradu-
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ally grows the whole chromosome as follows: for markers on the 
right side of the disease locus, it generates an allele at locus  d +  i 
given the haplotype at [ d +  i  – 4,  d +  i – 1] for  i  6 3; the condi-
tional probabilities for the alleles at locus  d +  i given the haplotype 
at [ d +  i  – 4,  d +  i – 1] are determined based on the HapMap phased 
data. Similarly, for markers on the left side of the disease locus, it 
generates an allele at locus  d  –  i  given the haplotype at [ d –  i + 1, 
 d –  i + 4] for  i  6 3. Genotypes for non-disease chromosomes were 
generated similarly except that a randomly selected SNP was des-
ignated as the starting SNP.











































s = 1.02, GRR1 = 1.36, GRR2 = 1.84, MAF = 0.25
s = 1.02, GRR1 = 1.36, GRR2 = 1.84, MAF = 0.25 s = 1.05, GRR1 = 1.58, GRR2 = 2.44, MAF = 0.31
s = 1.02, GRR1 = 1.34, GRR2 = 1.78, MAF = 0.33 s = 1.05, GRR1 = 1.58, GRR2 = 2.45, MAF = 0.30
s = 1.05, GRR1 = 1.57, GRR2 = 2.43, MAF = 0.43
Chr 6 – locus 1
46.8 47.2 47.6 48.0 48.4 48.8
Chr 3 – locus 4
68.2 68.6 69.0 69.4 69.8 70.2
Chr 10 – locus 2
46.2 46.6 47.0 47.4 47.8 48.2
Chr 11 – locus 5
164.6 165.0 165.4 165.8 166.2 166.6
Chr 5 – locus 3
Position (Mb)
39.2 39.6 40.0 40.4 40.8 41.2
Chr 4 – locus 6
Position (Mb)
 Fig. 1. Local LD patterns around the six disease loci used in simulations. Displayed is the pairwise  r 2  between 
the disease locus (solid grey line) and the SNPs on the HumanHap300 within 1 Mb from the disease locus (black 
dots).
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 Note that the simulated chromosomes generated by this algo-
rithm are not exact copies of those in the original HapMap sam-
ples. Rather, the 120 CEU founder chromosomes are used to gen-
erate plausible haplotypes in a wider population. This algorithm 
retains short-range LD patterns  [14] , upon which power is mostly 
determined.
 Test of Association and Power Estimation
 The disease locus genotypes were removed prior to data anal-
ysis. Allele frequencies in cases and controls were compared using 
a 1-d.f. chi-squared test. Markers with total allele count  ! 5 for any 
allele were excluded from analyses. On average, only two to three 
such SNPs were excluded because the HumanHap300 chip con-
sists mostly of SNPs with MAF  6 0.05. The FDR level used in all 
the procedures was  q = 0.05. A success was declared if a signifi-
cantly associated SNP was within 1 Mb from the disease locus. 
The power to detect association was computed as the fraction of 
successes among all replicate data sets.
 Definition of Prioritized Subset
 When defining the prioritized subset, we considered the fol-
lowing combinations: (i) the number of candidate regions in the 
prioritized subset (6, 14, 22); (ii) the size of the candidate regions 
(2 Mb, 20 Mb), and (iii) the number of disease loci included in the 
prioritized subset. The 2 Mb regions may resemble those deter-
mined on the basis of candidate genes, whereas the 20 Mb regions 
may be typical for those identified through linkage studies. If a 
region contained a disease locus, it was defined to be centered on 
the disease locus; candidate regions not containing any disease 
locus were picked randomly in the genome. All the candidate re-
gions were unlinked to each other.
 Several criteria can guide the choice of how many disease loci 
are included in the prioritized subset. Because the prioritized 
subset will likely include regions identified through previous 
linkage or associated studies, we considered the relative likeli-
hood for our simulated disease loci to be identified in previous 
studies. Disease loci with strong effects are more likely to be iden-
tified than those with weak effects, and given the same marginal 
effect, disease loci in regions of strong LD are more likely to be 
identified in association studies than those in regions of weak 
LD. Following these rationale, we considered a variety of sce-
narios and defined the prioritized subset to include the three 
large effect disease loci and various numbers of the small effect 
disease loci. We also considered scenarios to examine the effect 
of exclusion of disease loci from the prioritized subset. Altogeth-
er, the following eight scenarios were considered ( fig. 2 ,  3 ), with 
increasing number of disease loci included in the prioritized sub-
set: (i) no disease loci; (ii) one large effect disease locus (locus 6); 
(iii) one large and one small effect disease loci (loci 1 and 6); (iv) 
two large and two small effect disease loci (loci 1, 2, 5, and 6); (v) 
the three large effect disease loci (loci 4, 5, and 6); (vi) the three 
large effect and one small effect disease loci (loci 1, 4, 5, and 6); 
(vii) the three large effect and two small effect disease loci (loci 
1, 2, 4, 5, and 6), and (viii) all six disease loci. Note that our cur-
rent knowledge may be limited so that only a small fraction of 
disease loci will be included in the prioritized subset. Nonethe-
less, these eight scenarios allow us to evaluate PSA under a broad 
range of possibilities.
 Results
 Power of the PSA
 Figure 2 displays the estimated power of the PSA and 
the WGA when candidate region sizes were 2 Mb, and 
 figure 3 displays the power when candidate region sizes 
were 20 Mb. As expected, the PSA is more powerful than 
the WGA for the disease loci that are included in the pri-
oritized subset. For example, the power to detect disease 
locus 1 was 12% in the WGA, but it increased substan-
tially when disease locus 1 was included in the prioritized 
subset. In scenarios (vi)–(viii) in which the prioritized 
subset had six candidate regions including disease locus 
1 and the three large-effect disease loci, the power to de-
tect disease locus 1 increased to 38% when the region siz-
es were 20 Mb ( fig. 3 ), and further increased to 72% when 
the region sizes were 2 Mb ( fig. 2 ). Clearly, if a prioritized 
region contains a disease locus, then a narrower region 
will lead to greater power improvement due to increased 
precision and a resulting smaller proportion of non-as-
sociated markers in the prioritized subset.
 The power improvement also depended on how many 
other disease loci were included in the prioritized subset. 
For example, when the prioritized subset had six candi-
date regions and the region sizes were 2 Mb ( fig. 2 ), the 
power to detect disease locus 6 increased from 12% in the 
WGA to 28% when it was the only disease locus included 
in the prioritized subset (scenario (ii)), to 46% when dis-
ease locus 1 was also included (scenario (iii)), to 59% 
when disease loci 1, 2, 5 were included (scenario (iv)), and 
to 81% when all the other disease loci were included (sce-
nario (viii)).
 The effect size of the other disease loci that were in-
cluded in the prioritized subset also played a role. As an 
example, let us compare scenarios (iv) and (vi). Although 
both scenarios included disease locus 1 and three other 
disease loci, and both improved the power to detect dis-
ease locus 1 substantially, the magnitude of power im-
provement was quite different. When the prioritized sub-
set had six candidate regions and the region sizes were
2 Mb, for scenario (vi), which included all three relatively 
large effect disease loci, the power increased from 12% in 
the WGA to 72% in the PSA, whereas the power increased 
to only 52% for scenario (iv) in which disease locus 4 was 
replaced by disease locus 2, a locus with smaller effect.
 Moreover, the power improvement depends on how 
many non-disease regions were included in the priori-
tized subset; the more non-disease regions in the priori-
tized subset, the less improvement in power due to a high-
er proportion of non-associated markers in the priori-
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tized subset. For each of the scenarios we considered, as 
the number of candidate regions increased from 6 to 22, 
the magnitude of power improvement decreased ( fig. 2 , 
 3 ). Nonetheless, if all six disease loci were correctly in-
cluded in the prioritized subset (scenario (viii)), even 
when 16 other non-disease regions were also included, 
dramatic improvements in power could still be observed, 
especially when the prioritized region sizes were small.
 While inclusion of disease loci in the prioritized sub-
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Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Scenario (ii) Scenario (vi)
Scenario (iii) Scenario (vii)
Scenario (iv) Scenario (viii)
 Fig. 2. Power comparison between the PSA and the WGA when the candidate region sizes were 2 Mb. The ar-
rows indicate the disease loci that were included in the prioritized subset. 
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their exclusion incurs negligible power loss ( fig. 2 ,  3 ). 
For example, when none of the disease loci were includ-
ed in the prioritized subset (scenario (i)), the power of 
detecting association for all disease loci was almost the 
same as that of the WGA, regardless of the prioritized 
region size and the number of candidate regions in the 
prioritized subset. A similar phenomenon was observed 
for the weighted FDR procedure  [5, 6] in which down 
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Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Locus 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus 6
Scenario (ii) Scenario (vi)
Scenario (iii) Scenario (vii)
Scenario (iv) Scenario (viii)
 Fig. 3. Power comparison between the PSA and the WGA when the candidate region sizes were 20 Mb. The ar-
rows indicate the disease loci that were included in the prioritized subset.
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 As expected, the power of detecting association with a 
disease locus depends not only on the effect of the vari-
ant, but also on the LD pattern surrounding the disease 
locus. A consequence of high LD around a disease locus 
is that many SNPs on the chip may tag the disease locus 
with high  r 2 , providing multiple opportunities for the 
disease association to be detected, especially when the 
disease locus genotypes are not directly observed. For ex-
ample, when all six disease loci were included in the pri-
oritized subset (scenario (viii)), the power was 72% for 
disease locus 1 (in a strong LD region), whereas it was 






















































































































 Fig. 4. Overall FDR of the PSA when the candidate region sizes were 2 Mb.
 Prioritized Subset Analysis  Hum Hered 2008;65:129–141 137
the fact that they had the same genetic effect size. In ei-
ther situation, our results showed that the PSA could sub-
stantially increase power, especially for disease loci in a 
weak LD region or with small genetic effect.
 We repeated simulations with different MAFs and dis-
ease models, and observed similar pattern of power im-
provement for the PSA. These results suggest that the 
performance of PSA is robust to MAF and disease model 
(data not shown). We also repeated simulations with 100 
cases and 100 controls, and observed similar patterns of 
power improvement, but the magnitude of power was 






















































































































 Fig. 5. Overall FDR of the PSA when the candidate region sizes were 20 Mb.
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 Overall FDR in the PSA
 Our results ( fig. 4 and  5 ) indicate that the overall FDR 
is under control. In the scenarios we considered, the FDR 
in the prioritized subset was even smaller than the overall 
FDR. In general, informative partitioning and accurate 
prior knowledge about disease gene regions tend to yield 
smaller overall FDR. In the extreme situation in which 
the prioritized subset consisted of the six disease loci and 
the size of each candidate region was 2 Mb, the overall 
FDR was near 0%. When the number of candidate re-
gions and the region sizes increased, i.e., when the prior 
knowledge about the disease became less certain, the 
overall FDR increased. In most scenarios we considered, 
the overall FDR was greater than the FDR in both subsets, 
presumably because the overall fraction of false rejec-
tions tended to be dominated by the higher value of the 
fractions for the two subsets.
 The tendency that the overall FDR is greater than the 
FDR in each subset may be stronger when the number of 
subsets is greater than two, which might lead to non-neg-
ligible inflation of the overall FDR when the genome is 
partitioned into many subsets. Examination of this issue 
is important because, for example, one might choose to 
carry out the FDR procedure separately for each chromo-
some, effectively splitting the genome into 23 subsets. 
Therefore, we carried out further simulations. We simu-
lated 1,000 replicate data sets of  n cases and  n controls
( n = 500, 1,000), and partitioned the SNPs into 23 subsets, 
one for each chromosome. We then carried out the FDR 
procedure in each subset and calculated the overall FDR. 
 Figure 6 shows that this led to a substantial inflation in 
the overall FDR. When  n = 500, the overall FDR was 
13.9%, almost three times as much as the target FDR con-
trol level  q = 5%. As the sample size increased to  n = 1,000, 
the overall FDR was less inflated, but still was at about 
8%.
 Sun et al.  [8] demonstrated that the expected total 
number of true discoveries may increase as a result of the 
stratified FDR analysis. Here, we showed that the overall 
FDR also can increase as a result of stratification, pre-
sumably because the number of false discoveries might 
increase at a faster rate than the number of true discover-
ies as the number of subsets increases.
 Discussion
 GWAS generates massive amounts of data and as a re-
sult leads to a substantial multiple-testing problem. On 
the one hand, SNP panels with hundreds of thousands of 
SNPs are desired to ensure good coverage of the whole 
genome. On the other hand, these products result in a 
huge number of hypothesis tests that require appropriate 
adjustment. This problem is especially serious in GWAS, 
in which the SNP panels have variation in coverage across 
the genome and investigators typically have little control 
over what SNPs to type and what regions receive dense 
coverage, but at the same time are obligated to adjust for 
many tests. Regions with little relevance to a study might 
receive dense coverage and unnecessarily increase the 
number of tests. A common analysis strategy for GWAS 
is to perform association analysis for each SNP and adjust 
for multiple comparisons for all the tests in a single step, 
in which all SNPs are inherently treated equally. Such 
equal treatment of all SNPs is optimal only when all the 
SNPs have an equal chance, a priori, to be associated with 
the outcome, which is often not true given our prior 
knowledge about candidate genes and linked regions. We 
proposed the prioritized subset analysis (PSA) in which 
we define a prioritized subset to be comprised of SNPs in 
regions that may harbor disease genes and then carry out 
the FDR procedure in the prioritized subset and in the 
complementary non-prioritized subset, respectively.
 We have demonstrated that the PSA is more powerful 
than the whole-genome single-adjustment approach un-
der a variety of alternative models. The power improve-
ment can be substantial depending on how much prior 
information is available. More accurate prior informa-
tion leads to greater improvement in power. One conse-
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 Fig. 6. Overall FDR for analysis on 23 subsets. 
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es required to achieve a certain power can be greatly re-
duced for SNPs included in the prioritized subset. For 
example, disease locus 1 from our simulation would re-
quire about 1,200 cases and 1,200 controls to achieve 70% 
power to detect association. When prior information on 
candidate genes is mostly correct so that the prioritized 
subset consists of all disease genes, then the PSA can 
achieve similar level of power with only 500 cases and 500 
controls. A nice property of the PSA is that even if the 
prior knowledge is not accurate, for example, in the worst 
situation, when none of the disease variants are included 
in the prioritized subset, the power loss of the PSA is neg-
ligible. Similar phenomenon has been observed in weight-
ed FDR analysis  [5, 6] .
 The power of the PSA depends not only on the effect 
of the disease locus itself, but also on other factors, in-
cluding the sizes of the prioritized regions, the numbers 
of disease and non-disease regions in the prioritized sub-
set, and the effect sizes of the other disease loci included 
in the prioritized subset. All these factors determine the 
fraction of associated SNPs in the prioritized subset and 
their nominal power. In the FDR procedure, a test can 
‘borrow the strength’ of the other tests: the power in-
creases when the fraction of tests under the alternative 
hypotheses or their nominal power increases. The PSA 
improves power by taking advantage of this property. 
When the prioritized subset is defined such that it in-
cludes most disease gene regions or disease loci with rel-
atively strong effect, the prioritized subset will, compared 
to the whole set, have a denser fraction of tests under the 
alternative hypotheses or relatively higher nominal pow-
er among such tests. As a result, for a SNP that is includ-
ed in the prioritized subset, the PSA will likely have high-
er power to detect association with the disease than the 
WGA.
 The PSA differs from the previously proposed ap-
proaches  [5, 6, 8] . Genovese et al.  [5] and Roeder et al.  [6] 
proposed a weighted FDR approach and illustrated it by 
using prior linkage information to define weights for in-
dividual SNPs, effectively resulting in a less stringent 
threshold for SNPs within linkage peaks versus those 
outside. However, prior information regarding disease 
susceptibility loci often comes from multiple sources oth-
er than linkage. For example, we often have some bio-
logical hypotheses about the disease, which facilitate 
identification of candidate genes (e.g.,  KCNJ11 and 
 ABCC8 may be candidate genes for type 2 diabetes be-
cause they are the two subunits of the   -cell K ATP  chan-
nel). Results also may be available from previous associa-
tion studies for the trait of interest or other related traits 
(e.g., for type 2 diabetes,  CAPN10  [15] ,  HNF4   [16] , and 
 SLC30A8 and  HHEX  [13] ). Although the weighted FDR 
approach can be applied to SNPs outside linkage regions, 
it may be difficult to choose appropriate weights from 
among a variety of possible weighting schemes. As a re-
sult, researchers might find it daunting to use because 
they must not only choose which SNPs to receive higher 
weights as well as which weighting scheme to utilize, but 
they are also compelled to justify and interpret the im-
pact of all of the different weights. The PSA does not as-
sign different weights to different subsets of SNPs, rather 
the PSA simply involves categorizing SNPs into two dif-
ferent risk subsets (presumed high risk versus low risk). 
The weighted FDR could use a binary weighting scheme 
to differentiate between presumed high risk and low risk 
SNPs. However, it is important to note that the weighted 
FDR still performs a single FDR adjustment (for a set con-
taining both up-weighted high risk SNPs and down-
weighted low risk SNPs) while the PSA performs two sep-
arate FDR adjustments (one for the subset containing 
high risk SNPs and one for the subset containing low risk 
SNPs). It has been proven previously that the FDR for the 
weighted FDR method is well controlled  [5] and we have 
demonstrated via simulation that the overall FDR for 
PSA is also well controlled. Future studies should com-
pare the two different approaches in terms of statistical 
power over a wide range of alternative models and differ-
ent weighting schemes for the weighted FDR.
 Sun et al.  [8] stratified SNPs on their ‘qualities’ such as 
minor allele frequency, which has little to do with the 
SNPs’ potential functionality or the prior knowledge of 
trait-marker associations. As a result, their approach does 
not lead to noticeable power improvement. In practice, 
one would like to select out SNPs that are non-synony-
mous, have known functionality, or lie within candidate 
genes. In this paper, we showed that stratifying based on 
prior information pertaining to the genetics of the trait 
can be quite helpful. In addition, Sun et al.  [8] did not 
evaluate the effect of stratification on the overall FDR. 
They showed the stratified analysis may have the advan-
tage of having more true positives. However, at the same 
time, the number of false positives may also increase as 
the number of subsets increases, leading to inflation of 
the overall FDR, a quantity that we desire to control. Our 
results suggest that it is best to have a single prioritized 
subset so that a SNP can borrow the strength of the other 
SNPs included in the same subset. If the potentially as-
sociated SNPs were to be split into more than one subset, 
the overall strength may be diluted and the power advan-
tage of the PSA could be diminished.
 Li  /Li  /Lange  /Watanabe  
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 We feel it is necessary to provide some recommenda-
tions on how the PSA will be applied in practice. One of 
the major advantages of GWAS using commercial geno-
typing platforms is the transparency of the analytic de-
sign. Unlike individual candidate gene association stud-
ies, it is typically known how many SNPs, in total, have 
been studied in a GWAS. This transparency allows the 
scientific community to put into proper perspective the 
overall statistical significance of the findings. We believe 
the benefit of applying the PSA to GWAS data is compel-
ling. However, without careful consideration, the PSA 
could be exploited to show seemingly superior results, 
especially when one seeks to define the prioritized subset 
after looking at the data. A priori determination of the 
prioritized subset is necessary to maintain valid esti-
mates of statistical significance. To keep the transparency 
of GWAS, we recommend documenting the SNP subset 
assignments prior to conducting PSA. This can help en-
sure that the information used in prioritization is inde-
pendent of the observed p values  [8] . The prioritized sub-
set can be defined based on information from multiple 
sources. For example, linkage analysis results are useful 
for defining candidate regions, and genome annotation 
databases or previous published association findings are 
useful resources for defining candidate genes. Moreover, 
one might partition the genome in a greedy way such that 
the prioritized subset contains a small number of regions. 
Although this increases the power for the SNPs included 
in the prioritized subset, it offers no power gain for other 
potential genes and regions that are excluded. Thus, in 
the absence of good a priori information, such greedy 
partitioning likely will not help much and should be dis-
couraged.
 For multiple outcome variables, the need to partition 
the tests into more than two subsets may arise. Sun et al. 
 [8] described a situation in which 1,500 SNPs were ana-
lyzed to look for correlation with five outcome variables. 
For each outcome variable, there were 1,500 tests. One 
could carry out a single FDR adjustment for all 7,500 
tests, or five separate FDR adjustments, one for each out-
come variable. Because the numbers of associated SNPs 
may vary substantially across the five variables, Sun et al. 
 [8] demonstrated it would be more powerful to carry out 
separate adjustment. However, we caution that analysis 
on many subsets may lead to inflation of the overall 
FDR.
 In principle, the PSA can be applied to situations in 
which multiple hypothesis tests are performed and the 
investigator has a prior knowledge on the relative likeli-
hood for the tests to lead to significant results. For ex-
ample, when studying gene-gene or gene-environment 
interactions, it would be desirable and probably more 
powerful to define a prioritized subset consisting of plau-
sible combinations of gene-gene or gene-environment 
pairs than considering all possible pairs in a single adjust-
ment. In candidate gene studies, investigators may rely on 
cost-efficient multiplex genotyping assays that will geno-
type a fixed number of SNPs at a time. Often the number 
of SNPs an investigator is willing to genotype is not ex-
actly the allowed number on the assay, and adding SNPs 
to fill the assay would incur little additional costs. In this 
situation, investigators often choose to fill in the spaces 
with ‘extra’ SNPs, which they may not have chosen to 
genotype if substantial cost were involved. In other words, 
these additional SNPs may have relatively lower priority 
compared to the originally selected ones. In this situa-
tion, a single adjustment for multiple testing for all the 
SNPs may lower the power for the originally selected 
SNPs, and the PSA would be a more powerful alterna-
tive.
 When external information is available, it is often de-
sirable to incorporate such information into analysis so 
that more efficient use of the full genomic data can be 
achieved. The PSA takes into account prior information 
on candidate genes and linked regions by defining a pri-
oritized subset to comprise the SNPs falling in these re-
gions. Some other methods have also been developed to 
combine prior information into analysis, for example, ge-
nomic convergence  [17] and the weighted FDR procedure 
 [5, 6] . The PSA is a powerful, intuitive, and easily imple-
mented approach for GWAS. Furthermore, the PSA has 
the flexibility of allowing the investigators to combine 
prior information from a variety of sources and does not 
require assigning different combinations of weight fac-
tors. We believe that the PSA will be a useful addition to 
the existing toolbox of statistical methods.
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